SCHEMBL2731945

SCHEMBL2731945

CCCCCCCCCCCCCCCC1=C(C(=O)O)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 6/20 0.46
CDC25B P30305 6/20 0.46
CDC25C P30307 5/20 0.46
SCD O00767 1/20 0.43
RARB P10826 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RARA P10276 1/20 0.42
MAPT P10636 1/20 0.42
MTOR P42345 1/20 0.42
PPARG P37231 4/20 0.40
PPARD Q03181 4/20 0.40
PPARA Q07869 4/20 0.40
TSHR P16473 3/20 0.40
GPR84 Q9NQS5 3/20 0.40
HDAC11 Q96DB2 3/20 0.40
BID P55957 2/20 0.40
BCL2L1 Q07817 2/20 0.40
MCL1 Q07820 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40469 1.00 CDC25A (0.46) CDC25ACDC25BCDC25CSCDRARB
SCHEMBL6433540 1.00 CDC25A (0.46) CDC25ACDC25BCDC25CSCDRARB
SCHEMBL10618311 0.98 CDC25A (0.43) CDC25ACDC25BCDC25CSCDRARB
SCHEMBL9332691 0.83
SCHEMBL7058414 0.82 CDC25A (0.41) CDC25ACDC25BCDC25CSCDRARB
SCHEMBL5269756 0.79 CDC25A (0.39) CDC25ACDC25BCDC25CSCDPPARG
SCHEMBL2128309 0.74 GPR84 (0.65) CDC25ACDC25BCDC25CSCDALDH1A1
SCHEMBL6478501 0.72 SCD (0.43) CDC25ACDC25BCDC25CSCDRARB
SCHEMBL14989170 0.68 BID (0.51) SCDRARBALDH1A1MEN1KMT2A
SCHEMBL19406563 0.68 BID (0.51) SCDRARBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116271263-B Composite reinforced degradable material and preparation method and application thereof 广州医科大学 2024-09-13 CN claimed
CN-116271263-A Composite reinforced degradable material and preparation method and application thereof 广州医科大学 2023-06-23 CN claimed
US-20230059978-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2023-02-23 US claimed
EP-4087915-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS Guiliano, Shayne (US) 2022-11-16 EP claimed
WO-2021142241-A1 LIVE CELL CONSTRUCTS FOR BIOSYNTHETIC MILK PRODUCTION AND RELATED PRODUCTS AND METHODS GUILIANO SHAYNE (US) 2021-07-15 WO claimed
EP-3515498-B1 INHIBITORS OF GPR132 FOR USE IN PREVENTING AND/OR TREATING CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN FRAUNHOFER GES FORSCHUNG (DE) 2021-03-03 EP claimed
EP-3515498-A1 INHIBITORS OF GPR132 FOR USE IN PREVENTING AND/OR TREATING CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN Fraunhofer Gesellschaft zur Förderung der angewandten Forschung E.V. (DE) 2019-07-31 EP claimed
US-20190211397-A1 INHIBITORS OF GPR132 FOR USE IN PREVENTING AND/OR TREATING CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2019-07-11 US claimed
CN-109715212-A For preventing and/or treating the GPR132 inhibitor of neuropathic pain caused by chemotherapy 弗劳恩霍夫应用研究促进协会 2019-05-03 CN claimed
WO-2018055082-A1 INHIBITORS OF GPR132 FOR USE IN PREVENTING AND/OR TREATING CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2018-03-29 WO claimed
EP-3299032-A1 INHIBITORS OF GPR132 FOR USE IN PREVENTING AND/OR TREATING CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2018-03-28 EP claimed
CN-116271263-B Composite reinforced degradable material and preparation method and application thereof 广州医科大学 2024-09-13 CN disclosed
CN-116271263-B Composite reinforced degradable material and preparation method and application thereof 广州医科大学 2024-09-13 CN disclosed
CN-118542862-A Application of pinocembrin in preparation of aromatic hydrocarbon receptor regulator 中国科学院华南植物园 2024-08-27 CN disclosed
CN-117007728-A Method for simultaneously analyzing common free oxidized lipid and precursor compound of breast milk or milk powder sample 黑龙江飞鹤乳业有限公司 2023-11-07 CN disclosed
WO-2014111465-A1 ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI (FR) 2014-07-24 WO disclosed
EP-1931201-B1 USE OF SEH INHIBITORS AS ANALGESICS UNIV CALIFORNIA (US) 2012-05-02 EP disclosed
US-20080249055-A1 Use of Seh Inhibitors as Analgesics NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-10-09 US disclosed
EP-1931201-A2 USE OF SEH INHIBITORS AS ANALGESICS The Regents of the University of California (US) 2008-06-18 EP disclosed
WO-2007022509-A2 USE OF SEH INHIBITORS AS ANALGESICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249055-A1 Use of Seh Inhibitors as Analgesics EPHX1, FAAH, EPHX2 CDC25A 2647/4885CDC25B 2286/4885CDC25C 3289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.